This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
This year at The Liver Meeting, data presented on hepatitis C treatment highlighted continued significantly positive outcomes from direct-acting antiviral therapy, reduced rates of hepatocellular carcinoma, and improved outreach and screening techniques.
Healio Gastroenterology and Liver Disease has compiled the following reports which include presentations on nearly perfect sustained virologic response rates with Mavyret for 8 weeks, failure and retreatment outcomes in patients with NS5A substitutions, and results from a telemedicine program:
- Preemptive DAA therapy improves outcomes of negative-to-positive HCV heart transplant
- EXPEDITION-8: Mavyret nearly perfect in 8-week regimen
- NS5A substitutions affect early HCV treatment failures, retreatment
- DAAs reduce HCC, decompensation risk compared with no treatment
- HCV telemedicine program satisfying, cost-effective in Spanish prison
- HCV reinfection uncommon in injection drug users after treatment
- Universal screening for HCV superior to risk-based approach in pregnant women